Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients with hereditary BRCA mutations respond less well to conventional treatment

Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy - and they also have a lower survival rate than those who are non-carriers of these genetic mutations. Data from the study, which has been published in the journal European Urology, points to the need for new clinical trials aimed at targeting these mutations in order to tailor treatment for these patients. [More]
New technology improves lung cancer detection during radiation therapy

New technology improves lung cancer detection during radiation therapy

Researchers from Loyola University Chicago Stritch School of Medicine have developed a technology that improves the detection of tumors during radiation therapy for early-stage lung cancer. [More]
New anti-cancer drug may protect normal cells against radiation

New anti-cancer drug may protect normal cells against radiation

Although radiation treatments have become much more refined in recent years, it remains a challenge to both sufficiently dose the tumor while sparing the surrounding tissue. [More]
Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Pretreatment interstitial lung disease (ILD) is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT) alone. [More]
ViewRay's MRIdian system gets CE Mark approval

ViewRay's MRIdian system gets CE Mark approval

ViewRay, a privately held medical device company, announced today that its MRIdian (me-rid-i-an) system, the world's first and only MRI-guided radiation therapy system, has received CE Mark (Conformite Europeenne) approval. [More]
Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's starts patient enrollment for immunotherapy clinical trial for neuroblastoma

Seattle Children's today announced the opening of patient enrollment for its new cellular immunotherapy clinical research trial designed to induce remission in children suffering from neuroblastoma, one of the deadliest forms of childhood cancer. [More]
APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

APBI with proton therapy less costly than other traditional treatments for early stage breast cancer

In terms of duration of treatment and cost, patients with early stage breast cancer may benefit from accelerated partial breast irradiation (APBI) with proton therapy versus whole breast irradiation (WBI), according to new research from The University of Texas MD Anderson Proton Therapy Center. [More]
PORT can improve survival for non-small cell lung cancer patients

PORT can improve survival for non-small cell lung cancer patients

Patients who received post-operative radiation therapy (PORT), radiation therapy after surgery, lived an average of four months longer when compared to the patients who had the same disease site, tumor histology and treatment criteria and who did not receive PORT, according to research presented today at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology. [More]
New Clinical Practice Guideline for diagnosis, treatment of acromegaly

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of acromegaly, a rare condition caused by excess growth hormone in the blood. [More]

STS releases new clinical practice guidelines for treating esophageal cancer

The Society of Thoracic Surgeons has released new clinical practice guidelines for treating cancer of the esophagus and gastroesophageal junction (area where the esophagus meets the stomach). [More]
Patients who receive chest radiation for Wilms tumor face breast cancer risk later in life

Patients who receive chest radiation for Wilms tumor face breast cancer risk later in life

A new study has found that patients who received chest radiation for Wilms tumor, a rare childhood cancer, face an increased risk of developing breast cancer later in life due to their radiation exposure. [More]

BRI receives FDA permission to conduct study of Antineoplastons A10 and AS2-1 in DIPG patients

Burzynski Research Institute, Inc. announced today that the U.S. Food and Drug Administration has given the company permission to conduct an open-label study of Antineoplastons A10 and AS2-1 in patients > 3 months of age with a diffuse intrinsic brainstem glioma (DIPG). [More]
The PROBEAT-RT Proton Beam Therapy System incorporating real-time tumor-tracking is approved in Japan

The PROBEAT-RT Proton Beam Therapy System incorporating real-time tumor-tracking is approved in Japan

Hokkaido University and Hitachi, Ltd. have announced that the approval under Japan’s Pharmaceutical Affairs Law has been granted to Hitachi for the manufacture and sales of the PROBEAT-RT, a proton beam therapy treatment system combining spot scanning irradiation and Real-time Tumor-tracking Radiation Therapy. [More]
Genetic changes in blood cells of older people linked to lymphoma, leukemia

Genetic changes in blood cells of older people linked to lymphoma, leukemia

At least 2 percent of people over age 40 and 5 percent of people over 70 have mutations linked to leukemia and lymphoma in their blood cells, according to new research at Washington University School of Medicine in St. Louis. [More]
New study reviews modern treatment modalities for early-stage lung cancer

New study reviews modern treatment modalities for early-stage lung cancer

Removal of the entire lobe of lung may offer patients with early-stage lung cancer better overall survival when compared with a partial resection, and stereotactic ablative radiotherapy (SABR) may offer the same survival benefit as a lobectomy for some patients, according to a study from The University of Texas MD Anderson Cancer Center. [More]
AirXpanders' AeroForm expander shows superior outcomes in patients undergoing breast reconstruction

AirXpanders' AeroForm expander shows superior outcomes in patients undergoing breast reconstruction

The latest interim data from XPAND, AirXpanders Inc.’s U.S.-based, head-to-head pivotal study of its new, needle-free, patient-controlled tissue expansion system for mastectomy patients undergoing breast reconstruction, continue to show superior outcomes compared to traditional saline expanders including dramatically shorter expansion times, according to updated clinical data results presented at Plastic Surgery The Meeting, the annual scientific meeting of the American Society of Plastic Surgeons. [More]
Champalimaud Foundation to establish cancer institute in Rajasthan, India

Champalimaud Foundation to establish cancer institute in Rajasthan, India

The Lisbon based Champalimaud Foundation has entered into a partnership with the Government of Rajasthan, India, to establish a state-of-the–art cancer institute with world-class facilities. [More]
Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S. [More]
IRCM researchers discover mechanism that promotes progression of medulloblastoma

IRCM researchers discover mechanism that promotes progression of medulloblastoma

Scientists at the IRCM discovered a mechanism that promotes the progression of medulloblastoma, the most common brain tumour found in children. The team, led by Fr-d-ric Charron, PhD, found that a protein known as Sonic Hedgehog induces DNA damage, which causes the cancer to develop. [More]
Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

Groups urge Medicare to cover LDCT screening for adults at high risk for lung cancer

More than 60 patient advocacy and medical organizations have joined a coalition headed by the Lung Cancer Alliance, the American College of Radiology and The Society of Thoracic Surgeons, in urging Medicare to cover low dose computed tomography (LDCT) screening for beneficiaries at high risk for lung cancer. [More]